ArticleOncogene2017
HBEGF promotes gliomagenesis in the context of Ink4a/Arf and Pten loss.
Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Identifying the therapeutic effects of talniflumate in metastatic papillary thyroid microcarcinoma through integrating multiple omics analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Manganese-Templated Nontrivial Structures for MRI and Therapy.Journal of the American Chemical Society · 2026Article
- Therapeutic Reprogramming of Glioblastoma Phenotypic States Using Multifunctional Heparin Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Integrated multi-omics analysis and experimental validation identify hub genes with diagnostic value in meningitis.Frontiers in cellular and infection microbiology · 2026Article
- Machine learning identifies inflammation-related diagnostic biomarkers for primary myelofibrosis with clinical validation.Scientific reports · 2025Article
- Discovery of miRNA-mRNA regulatory networks in glioblastoma reveals novel insights into tumor microenvironment remodeling.Scientific reports · 2024Article
- microRNA-194 is increased in polycystic ovary syndrome granulosa cell and induce KGN cells apoptosis by direct targeting heparin-binding EGF-like growth factor.Reproductive biology and endocrinology : RB&E · 2021Article
- MeCP2 drives hepatocellular carcinoma progression via enforcing HOXD3 promoter methylation and expression through the HB-EGF/EGFR pathway.Molecular oncology · 2021Article
- Induction of cellular senescence in fibroblasts through β1-integrin activation by tenascin-C-derived peptide and its protumor effect.American journal of cancer research · 2021Article
- Prognostic Implication of the Expression Level of PECAM-1 in Non-small Cell Lung Cancer.Frontiers in oncology · 2021Article
- Article
- A map of tumor-host interactions in glioma at single-cell resolution.GigaScience · 2020Article
- SOX2 Promotes Brain Metastasis of Breast Cancer by Upregulating the Expression of FSCN1 and HBEGF.Molecular therapy oncolytics · 2020Article
- Attenuated diphtheria toxin mediates siRNA delivery.Science advances · 2020Article
- MiR-376c-3p targets heparin-binding EGF-like growth factor (HBEGF) to inhibit proliferation and invasion in medullary thyroid carcinoma cells.Archives of medical science : AMS · 2020Article
- PD-L1 Inhibitor Regulates the miR-33a-5p/PTEN Signaling Pathway and Can Be Targeted to Sensitize Glioblastomas to Radiation.Frontiers in oncology · 2020Article
- Mutant IDH1 Promotes Glioma Formation In Vivo.Cell reports · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Heparin-binding epidermal growth factor (EGF)-like growth factor (HBEGF) is a ligand for the EGF receptor (EGFR), one of the most commonly amplified receptor tyrosine kinases (RTKs) in glioblastoma (GBM). While HBEGF has been found to be expressed in a subset of malignant gliomas, its sufficiency for glioma initiation has not been evaluated. In this study, we demonstrate that HBEGF can initiate GBM in mice in the context of Ink4a/Arf and Pten loss, and that these tumors are similar to the classical GBM subtype observed in patients. Isogenic astrocytes from these mice showed activation not only of Egfr but also the RTK Axl in response to HBEGF stimulation. Deletion of either Egfr or Axl decreased the tumorigenic properties of HBEGF-transformed cells; however, only EGFR was able to rescue the phenotype in cells lacking both RTKs indicating that Egfr is required for activation of Axl in this context. Silencing of HBEGF in vivo resulted in tumor regression and significantly increased survival, suggesting that HBEGF may be a clinically relevant target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.